06th week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170035788 | Vesicular Formulations - Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea. | 2017-02-09 |
20170035789 | Composition Of Dietary Supplements Based On Apoptosis that Support Optimal Health - This invention clearly identifies the current agriculture-based diseases facing United States citizens such as, heart disease, stroke, cancer, diabetes and other degenerative diseases that did not exist in our hunter-gatherer ancestors. The United States government has established the Dietary Guidelines Advisory Committee (DGAC) to solve the problem. The DGAC's approach includes exercise, better agricultural based food choices plus vitamins-mineral supplements that are sex and age adjusted. We designed supplement compositions composed of unmodified dried fruits, herbs, including roots and tubers, many of which contain a lot of phytoestrogens. Currently, the medical profession has a bias against phytoestrogens, based on science that we believe is incorrectly interpreted. Today, women are afraid of getting breast cancer, and men are afraid of getting enlarged breasts from phytoestrogens. We will reinterpret the pre-clinical medical studies to alleviate these accepted concerns. Our supplement ingredients are chosen based on the different apoptosis pathways, which they stimulate, modulate or inhibit. | 2017-02-09 |
20170035790 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS - The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog. | 2017-02-09 |
20170035791 | COMBINATION OF BETA-GLUCOSYLCERAMIDE AND POLYETHOXYLATED CASTOR OIL AND OTHER ADJUVANTS FOR CONTROLING BLOOD SUGAR LEVELS, IMMUNOPROTECTION AND HEPATOPROTECTION - The disclosure relates to compositions and methods for adding beta glucosylceramide and/or Cremophor EL (CE), or an adjuvant selected from polyethylene glycol and beta cyclo dextrin or any type of beta or alpha glucosylceramide with/without CE, or CE alone, to drinks or foods to serve as liver protectors, sugar protectors, and anti inflammatory protectors. | 2017-02-09 |
20170035792 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THE TREATMENT OF AUTISTIC SYNDROME DISORDERS - The present invention relates to a method for the treatment of an autistic syndrome disorder comprising administering to a subject in need thereof an effective amount of antibacterial agent. | 2017-02-09 |
20170035793 | Use of P2X Purinergic Receptor Agonists to Enhance Insulin Secretion In Pancreatic Beta Cells - Pharmaceutical compositions containing P2X purinergic agonists, e.g. P2X3 agonists, for increasing insulin secretion in a subject, methods of use, and methods of screening for related compounds and agents. | 2017-02-09 |
20170035794 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein - Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders. | 2017-02-09 |
20170035795 | METHODS AND REAGENTS FOR THE DIAGNOSIS AND TREATMENT OF ACUTE LEUKEMIA - The present invention is directed to methods of treating T-ALL that involves administering a therapeutic agent that inhibits a NOTCH-1 regulated non-coding RNA (lncRNA). Another embodiment of the invention relates to methods and kits for diagnosing T-ALL that involve detecting and quantifying the expression level of NOTCH1-regulated lncRNAs is a biological sample from a subject. | 2017-02-09 |
20170035796 | RNAi Therapy for Hepatitis B Virus Infection - Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment. | 2017-02-09 |
20170035797 | COMBINATION CANCER TREATMENTS UTILIZING SYNTHETIC OLIGONUCLEOTIDES AND EGFR-TKI INHIBITORS - The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a synthetic oligonucleotide. | 2017-02-09 |
20170035798 | MODULATION OF FACTOR 11 EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism. | 2017-02-09 |
20170035799 | COMBINATION OF GLYCOSAMINOGLYCANS AND CYCLODEXTRINS - The invention relates to an injectable combination of two specific glycosaminoglycans, hyaluronic acid and chondroitin sulfate, with cyclodextrins and the use of the combination for the treatment of diseases related to the skeletal systems, particularly in the intra-articular treatment, as well as in the intradermal treatment. | 2017-02-09 |
20170035800 | Reduction of Oxalate Absorption in Individuals - In various implementations, an oxalate absorption blocking (OAB) composition may be administered to improve a health of an individual. The OAB composition may include calcium and/or magnesium. In some implementations, the OAB composition may include one or more carbonates, probiotics, vitamins and/or other minerals. A therapeutically effective amount of the OAB composition may be administered to reduce oxalate absorption from foods consumed by an individual. Reducing oxalate absorption from foods consumed by an individual may decrease pain, improve movement of joints, inhibit kidney stone formation, and/or otherwise improve an individual's health. | 2017-02-09 |
20170035801 | ANTI-ITCHING AGENT - The present invention relates to an anti-itching agent that prevents itch of skin. An emulsion, which is produced when sebum and sweat continuously secreted are mixed, contains a stimulatory composition having aqueous and oily properties and can be a causative agent of itch. In addition, the emulsion can be a cell disorder composition. Furthermore, the emulsion causes itching and becomes a causative agent triggering and promoting dermatitis. The problem can be solved by blocking the emulsion by a skin-degenerative stratum corneum, which is formed by an action of an aluminum chloride and water, the aluminum chloride and a cyclodextrin. | 2017-02-09 |
20170035802 | METHOD FOR TREATING ITCHING - The present invention relates to an anti-itching agent that prevents itch of skin and a method for treating itching. An emulsion, which is produced when sebum and sweat continuously secreted are mixed, contains a stimulatory composition having aqueous and oily properties and can be a causative agent of itch. In addition, the emulsion can be a cell disorder composition. Furthermore, the emulsion causes itching and becomes a causative agent triggering and promoting dermatitis. The problem can be solved by blocking the emulsion by a skin-degenerative stratum corneum, which is formed by an action of an aluminum chloride and water, the aluminum chloride and a cyclodextrin. A polyphenol compound or a tannic acid can be also contained. | 2017-02-09 |
20170035803 | INSULIN-MIMETIC LOCAL THERAPEUTIC ADJUNCTS FOR ENHANCING SPINAL FUSION - Bone tissue materials comprising insulin-mimetic agents, such as suitable zinc, vanadium, tungsten, molybdenum, niobium, selenium, and manganese compounds, for facilitating spinal fusion of vertebrae M spinal fusion surgical procedures, and methods thereof. Additionally provided is a bone tissue kit for facilitating fusion of vertebrae in a spinal fusion surgical procedure including a composition formulated for facile application in a spinal fusion procedure comprising an insulin-mimetic agent and a pharmaceutically acceptable carrier. Yet further provided is an implantable device for enhancing spinal fusion including a prosthetic implant configured to stabilize and promote the fusion of two adjacent vertebrae, wherein the bone tissue contacting surfaces of the prosthetic implant are coated with a composition comprising an insulin-mimetic agent. | 2017-02-09 |
20170035804 | METHODS FOR INHIBITING COMPLEMENT ACTIVATION AND USES THEREOF - The present invention provides methods for inhibiting complement activation and uses thereof. More specifically, the present invention provides methods for inhibiting complement activation using inorganic polyphosphates of at least 10 phosphate units. The polyphosphates inhibit complement activation by one or more of: binding to the C6 complement protein, C1-esterase inhibitor (C1-inh), factor H or factor B; enhancing the activity of C1-inh; interfering with C1s-mediated cleavage of C2; destabilizing the C5b-6 complement protein complex; interfering with C5b,6 interaction with C7; interfering with binding of C5b-7 to a cell membrane; interfering with integration of C5b-7 into a cell membrane; interfering with binding of C5b-8 to a cell membrane; interfering with integration of C5b-8 into a cell membrane; destabilizing the membrane attack complex (MAC); or reducing the amount of C5b-9 deposited on a cell surface. | 2017-02-09 |
20170035805 | BIOACTIVE GLASS PREPARATION AND USE - A process of preparing a glass comprising: (a) heating a mixture of precursor chemicals to a melt temperature to form a melt, the melt being characterized in that quenching the melt at or above a threshold temperature results in a spinodal phase separation, and quenching the melt below the threshold temperature results in a droplet phase separation; and (b) quenching the melt at or above the threshold temperature in a preheated mold to form the glass composition having the spinodal phase separation. | 2017-02-09 |
20170035806 | COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF BONE DISORDERS - A composition for use in medicine or as a dietary supplement, the composition including at least one complex or salt of trivalent metal cation (Me | 2017-02-09 |
20170035807 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2017-02-09 |
20170035808 | REGULATORY T-CELLS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS OF THE HUMAN GASTROINTESTINAL TRACT - The present invention relates to a composition comprising an isolated CD4 | 2017-02-09 |
20170035809 | SERUM FRACTION OF PLATELET-RICH FIBRIN - The invention provides for a method of preparing an isolated serum fraction of platelet rich fibrin (PRF), comprising the steps of
| 2017-02-09 |
20170035810 | COMPOSITIONS AND METHODS FOR TREATING ITCHING, GINGIVOSTOMATITIS, AND DEMODECTIC MANGE - Provided are methods for treating itching caused by allergy, include itching associated with parasite-mediated inflammation (e.g., demodicosis, stomatitis, dermatophytosis, etc.), comprising administration to a mammalian subject in need thereof a therapeutically effective amount of a heat-treated, fractionated thymus extract composition (e.g., Thyex-1-6A and -6B compositions, comprising proteins or polypeptides having molecular weights in the range of 3.5 kDa to 30 kDa), in combination with or formulated with colostrum, to provide for reducing itching in the subject. Combination or adjunctive therapies comprising administration of a heat-treated, fractionated thymus extract composition in combination with or formulated with colostrum, and including at least one additional anti-parasitic, anti-bacterial, anti-fungal, anti-viral agent, or homeopathic agent are also provided. Methods of treating parasite-mediated inflammation, comprising administration of fractionated thymus extract compositions to reduce parasite-mediated inflammation are provided. | 2017-02-09 |
20170035811 | Treatment Of Vocal Cords With Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 2017-02-09 |
20170035812 | Novel cell-derived composition - The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair. | 2017-02-09 |
20170035813 | METHODS FOR THE DIETARY MANAGEMENT OF IRRITABLE BOWEL SYNDROME AND CARBOHYDRATE MALABSORPTION - The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a | 2017-02-09 |
20170035814 | NOVEL LACTIC ACID BACTERIUM AND USE THEREOF | 2017-02-09 |
20170035815 | NOVEL LACTOBACILLUS PLANTARUM AND COMPOSITION CONTAINING SAME - The present invention provides | 2017-02-09 |
20170035816 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease. | 2017-02-09 |
20170035817 | NOVEL BACTERIOPHAGE AND COMPOSITION COMPRISING SAME - The present invention relates to a novel bacteriophage ΦCJ27 (KCCM11465P) and a composition containing the same as an active ingredient. Further, the present invention relates to a method for preventing and/or treating infective diseases caused by enterotoxic | 2017-02-09 |
20170035818 | GROUP B ADENOVIRUS MODIFIED IN THE E4ORF4 REGION - The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer. | 2017-02-09 |
20170035819 | ONCOLYTIC HSV VECTOR - The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV. | 2017-02-09 |
20170035820 | Integrative fungal solutions for protecting bees and overcoming colony collapse disorder (CCD) - The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and mixtures of species, to provide an armamentarium of defenses from multiple stressors in order to help bees survive a complex of symptoms collectively called colony collapse disorder (CCD). More particularly, the present invention utilizes specific concentrations of extracts from pure cultured mycelium from mushroom forming fungi to reduce harmful viruses in bees and to increase the longevity of bees. | 2017-02-09 |
20170035821 | ANTI-CANDIDA COMPOSITIONS AND USES THEREOF - The present invention is directed to compositions, uses and methods useful in the prevention or treatment of | 2017-02-09 |
20170035822 | PHARMACEUTICAL COMPOSITION COMPRISING PISTACIA WEINMANNIFOLIA EXTRACT, FRACTION OF SAME OR COMPOUND SEPARATED FROM SAME FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising a | 2017-02-09 |
20170035823 | METHOD FOR TREATING OR SUPPRESSING DEGENERATIVE BRAIN DISEASES BY CHINESE HERBAL MEDICINE COMPOSITION - The present invention discloses a method for treating or suppressing degenerative brain diseases, comprising a step of administrating a Chinese herbal medicine composition to a subject in need, wherein the Chinese herbal medicine composition comprises: a first herbal formula comprising 2-40 parts by weight of | 2017-02-09 |
20170035824 | USAGE OF OBLONGIFOLIN C, A NATURAL COMPOUND FROM GARCINIA YUNNANENSIS HU, ON TREATING CANCER AS METASTASIS INHIBITOR AND AUTOPHAGIC FLUX INHIBITOR - Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising | 2017-02-09 |
20170035825 | FOOD SUPPLEMENT COMPOSITION COMPRISING A CUCUMBER (CUCUMIS SATIVUS) EXTRACT - There is described a food supplement composition comprising a cucumber ( | 2017-02-09 |
20170035826 | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ULCERS OF VARIOUS ORIGINS - The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use. | 2017-02-09 |
20170035827 | Compositions and Methods to Reduce Hangover and Reduce Blood Alcohol Levels After Alcohol Consumption - Compositions and methods for preventing and/or reducing hangover, when consumed before, after or during drinking alcohol. Compositions of the inventions include fructose powder, prickly pear extract, N-acetyl cysteine; kudzu; lemon balm; Vitamin C; nopal; white willow bark extract; milk thistle; Vitamin B1; Vitamin B6; lemon juice; acacia fiber; and other ingredients. | 2017-02-09 |
20170035828 | COMPOSITION CONTAINING SCUTELLARIA ALPINA EXTRACT - The present invention relates to a composition containing a | 2017-02-09 |
20170035829 | Compositions, Methods, and Medical Compositions for Treatment of and Maintaining the Health of the Liver - Compositions and methods for treatment of and maintaining the health of the liver are disclosed that include a mixture of plant extracts, wherein the plant extracts comprise at least one | 2017-02-09 |
20170035830 | COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE AND/OR INJURY - A method of treating heart disease and/or injury in a subject includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTPσ. | 2017-02-09 |
20170035831 | COMPOSITION COMPRISING BORTEZOMIB - The present invention relates to ready to dilute injectable formulations of bortezomib comprising bortezomib, non-aqueous solvents enhancing the solubility and pH modifying agent. | 2017-02-09 |
20170035832 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS - The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor. | 2017-02-09 |
20170035833 | METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST - The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist. | 2017-02-09 |
20170035834 | METHOD OF MANUFACTURE OF GNRH-CONTAINING GEL - The invention relates to compositions for synchronizing the time of insemination in an animal. More particularly, the invention relates to a process for manufacturing and stabilizing GnRH-containing compositions for use in synchronizing the time of insemination in an animal. | 2017-02-09 |
20170035835 | PEPTIDES AND METHODS OF USE - The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound. | 2017-02-09 |
20170035836 | COMPOSITIONS AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION - The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain. | 2017-02-09 |
20170035837 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) - The invention provides compositions and methods for reducing one or more symptoms of disease by administering compositions comprising SipA. The invention's compositions and methods are particularly advantageous in reducing symptoms of diseases that are associated with overexpression of P-gp and/or p53. The invention's compositions and methods are useful in reducing cancer symptom and/or cancer multidrug resistance (MDR). The invention provides a method for reducing one or more symptoms of cancer in a mammalian subject in need thereof, comprising administering to said subject a composition comprising purified SipA. In one embodiment, said SipA is operably conjugated to a nanoparticle. In another embodiment, said cancer comprises cancer cells resistant to at least one cytotoxin. | 2017-02-09 |
20170035838 | LYOPHILIZED FORMULATION OF TAT-NR2B9C - The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at room temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital. | 2017-02-09 |
20170035839 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE - Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease. | 2017-02-09 |
20170035840 | LIQUID ENTERAL NUTRITIONAL COMPOSITION WITH A LOW MONOVALENT METAL ION CONTENT - Heat-treated liquid enteral nutritional composition with a low monovalent metal ion content are provided that contain micellar casein and optionally caseinate, and in which the total amount of monovalent metal ions is less than 25 mg/g of protein. Also, heat-treated liquid enteral nutritional compositions are disclosed comprising 10 to 20 g of protein per 100 ml of the composition, in which all or a major part of said protein comprises micellar casein. Also, a method is disclosed for producing the composition according to the invention, comprising a step wherein an aqueous protein solution in which all or a major part of said protein comprises micellar casein, is subjected to an evaporation step. | 2017-02-09 |
20170035841 | TREATMENT OF MYOTONIC DYSTROPHY - The present invention relates to compositions and methods for treating myotonic dystrophy. | 2017-02-09 |
20170035842 | ApoO FOR USE IN A METHOD FOR TREATING CANCER AND VARIOUS PATHOPHYSIOLOGICAL SITUATIONS - The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to a compound for use for treating a pathophysiological situation, wherein said compound is an inhibitor of the ApoO activity or of the ApoO gene expression. | 2017-02-09 |
20170035843 | COMPOSITION TO REPURPOSE DRUGS - The invention in suitable embodiments is directed to purified non-cage clathrin protein compositions. In one aspect, one or more purified non-cage clathrin protein composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues, forms a composition to repurpose at least one aspect of a medicament or use thereof when the medicament is formulated with the non-cage clathrin protein. | 2017-02-09 |
20170035844 | BIOMARKERS FOR PAINFUL INTERVERTEBRAL DISCS AND METHODS OF USE THEREOF - The present disclosure provides methods of diagnosing painful intervertebral discs. The present disclosure also provides methods of treating a painful intervertebral disc. | 2017-02-09 |
20170035845 | Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression - θ-defensins, non-human macrocyclic peptides, have been found to reduce expression of genes encoding for various pro-inflammatory peptides (such as cytokines and chemokines) in a highly selective manner. Methods for treating inflammatory conditions utilizing a θ-defensin and/or a θ-defensin analog, methods for modifying (e.g. down regulating) gene expression for pro-inflammatory peptides in a subject in need thereof using a θ-defensin and/or a θ-defensin analog, methods for selectively modifying expression of such genes and/or reducing pro-inflammatory peptides in a subject without inducing or worsening immunosuppression using a θ-defensin and/or a θ-defensin analog are discussed, as are compositions that include a θ-defensin and/or a θ-defensin analog in an amount and/or form suitable for use in such methods. | 2017-02-09 |
20170035846 | PHARMACEUTICAL COMPOSITIONS CONTAINING BETA-2 MICROGLOBULIN AND METHODS OF TREATING AUTOIMMUNE DISEASES - A pharmaceutical product containing β2-microglobulin or a functional variant thereof as an active ingredient in the form of liposomes is provided. The product can increase the concentration of β2-microglobulin in the blood, and can also restore a normal HC/β2-microglobulin molar ratio within membrane MHC-I complexes, or prevent a β2-microglobulin deficit from occurring in the MHC-I complexes, of patients suffering from autoimmune diseases. Methods of treating patients with the pharmaceutical product are also presented. | 2017-02-09 |
20170035847 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION-ASSOCIATED DISORDERS OF THE GASTROINTESTINAL TRACT - Compositions and methods for treating inflammatory disorders of the GI tract are provided. The compositions include a therapeutically effective amount of TGFβ and ATRA (all-trans retinoic acid), in a pharmaceutically acceptable carrier suitable for oral administration. TGFβ and ATRA are preferably encapsulated in microspheres. | 2017-02-09 |
20170035848 | TREATMENT OF NEPHROPATHY - The present invention relates to the treatment of kidney diseases, both acute and chronic. The invention in particular relates to the use of neuregulins for preventing, treating or delaying kidney diseases. | 2017-02-09 |
20170035849 | METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS - The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases. | 2017-02-09 |
20170035850 | COMPOSITIONS FOR TREATING LUNG INFECTIONS BY AIRWAY ADMINISTRATION - The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of bacterial lung infections by administration via the airways. | 2017-02-09 |
20170035851 | Compositions And Methods For Treating Glioma - Isolated peptides, compositions and methods of use for treating tumors infiltrated with macrophages, such as glioblastomas. | 2017-02-09 |
20170035852 | METHODS AND USE OF GROWTH HORMONE SUPERGENE FAMILY PROTEIN ANALOGS FOR TREATMENT OF RADIATION EXPOSURE - Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed. | 2017-02-09 |
20170035853 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION - Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. | 2017-02-09 |
20170035854 | CONTROLLED OVARIAN HYPERSTIMULATION WITH IMPROVED RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE - The present invention pertains to methods for controlled ovarian hyperstimulation in a female subject using improved recombinant human follicle-stimulating hormone (rhFSH). The methods result in a high number of fertilizable oocytes even at low amounts of FSH administered to the female subject. | 2017-02-09 |
20170035855 | MEDICINAL AGENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS - A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof. | 2017-02-09 |
20170035856 | EXENATIDE-CONTAINING COMPOSITION AND PREPARATION METHOD THEREFOR - An exenatide-containing composition is in the form of microspheres, which are prepared by using exenatide acetate and polylactic-co-glycolic acid (PLGA) as raw materials, and the content of acetic acid in the prepared composition is lower than 0.01%. A method for preparing the exenatide-containing microspheres includes selecting a cleaning fluid of a proper external water Phase and a proper amount to clean microspheres, and selecting a proper re-drying temperature to cure the after the microspheres are freeze dried. | 2017-02-09 |
20170035857 | METHODS OF UPREGULATING IRS FUNCTION - This invention is directed to a general method for the chronic treatment, potential cure, or prevention of various metabolic and related diseases in people, including diabetes, by modulating IRS2 activity in cells and tissues in the body. IRS1 and IRS2 are part of the insulin or insulin-like growth factor signaling pathway. By upregulating the levels or functional activity of IRS2, insulin is used more efficiently by the body to control nutrient levels. By upregulating IRS2 levels or functional activity in pancreatic β-cells, glucose sensing and insulin secretion are enhanced. | 2017-02-09 |
20170035858 | MYOBLAST DIFFERENTIATION PROMOTER - A peptide selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof has a myoblast differentiation promoting effect superior to conventional arts. | 2017-02-09 |
20170035859 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS - Disclosed are compositions and methods for treating nephrogenic diabetes insipidus and for induction of diuretic effect. | 2017-02-09 |
20170035860 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROGENERATIVE DISEASES - Medical compositions and methods of treating or preventing neurodegeneration in a human suffering from or that is at risk of or susceptible to neurodegeneration or cellular dysfunction associated with expression or impaired cellular function of a neuronal protein encoded by one or more genes that code for alpha-synuclein (SNCA), Parkin RBR E3 ubiquitin protein ligase, (PARK2), Leucine-rich repeat kinase 2 (LRRK2), PTEN-induced putative kinase/(PINK1), Daisuke-Junko 1, (DJ-1) and ATPase type 13A2 (ATP13A2), are disclosed. Methods of treatment for these disorders is also provided, comprising administering a vector into a cell, wherein the vector facilitates expression of a molecular component that alters one of the aforementioned genes in the cell or expression of the gene in the cell, the gene being implicated in an etiology of the neurological deficit. | 2017-02-09 |
20170035861 | FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE - A flowable hemostatic gel composition is provided for use at a site of a defect within a biological tissue. The flowable hemostatic gel composition includes a flowable gel solution that includes a biopolymer dissolved in a first solvent. The biopolymer is configured to cross-link with red blood cells at the site to facilitate clot formation at the site. The flowable hemostatic gel composition also includes at least one additional active agent. | 2017-02-09 |
20170035862 | Use of APC analogue for wound healing - The present application relates to wound repair and wound healing by the application of a therapeutic amount of Activated Protein C-3K3A (‘APC-3K3A’). Specifically, this application is directed to a method of using APC-3K3A for the treatment of dermal or cutaneous wounds, including but not limited to, acute and chronic wounds, burns and ulcers. | 2017-02-09 |
20170035863 | Compositions Comprising Variegin - There is described variegin for use as a medicament in the treatment of disease or condition characterised in that the variegin is administered in an amount of at least about 0.1 mg/kg (mass of drug compared to mass of patient). | 2017-02-09 |
20170035864 | SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF - The invention provides vaccines containing, as its only active ingredient, a VLP having a CpG oligonucleotide attached thereto and a non-toxic pharmaceutically acceptable carrier or diluent and uses thereof. The invention further provides a pharmaceutical composition comprising a vaccine consisting of a VLP having a CpG oligonucleotide, one or more non-toxic pharmaceutically acceptable carrier or diluent, and a therapeutic agent admixture therewith and uses thereof. | 2017-02-09 |
20170035865 | IMMUNE RESPONSE INDUCER - An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). | 2017-02-09 |
20170035866 | METHOD FOR GENERATING IMMUNE CELLS RESISTANT TO ARGININE AND/OR TRYPTOPHAN DEPLETED MICROENVIRONMENT - The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies. | 2017-02-09 |
20170035867 | YEAST-BASED IMMUNOTHERAPY AND TYPE I INTERFERON SENSITIVITY - Disclosed are methods of treating individuals with yeast-based immunotherapy who have been preselected as being sensitive to type I interferons, as well as methods for selecting individuals for treatment with yeast-based immunotherapeutic compositions and methods for enhancing or improving an individual's response to yeast-based immunotherapy, based on the individual's sensitivity to type 1 interferons (T1IFNs). | 2017-02-09 |
20170035868 | IMMUNE RESPONSE INDUCER - An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). | 2017-02-09 |
20170035869 | IMMUNE RESPONSE INDUCER - An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). | 2017-02-09 |
20170035870 | Method for Proliferation of Antigen-Specific T Cells - The present invention relates to an in vitro method for priming genetically modified T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof. | 2017-02-09 |
20170035871 | MALARIA VACCINE - The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections. | 2017-02-09 |
20170035872 | COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE - The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such | 2017-02-09 |
20170035873 | METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE - This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided. | 2017-02-09 |
20170035874 | ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION - The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen. | 2017-02-09 |
20170035875 | Immune Enhancing Recombinant Dengue Protein - The invention relates to a method for preventing, ameliorating or treating disease caused by dengue virus in a subject in need thereof comprising administering to the subject a dengue vaccine formulation in combination with a NS3 helicase polypeptide and/or fragment(s) thereof, wherein said method comprises stimulating humoral as well as cell-mediated immunity to the dengue virus in the subject. | 2017-02-09 |
20170035876 | Influenza Vaccine and Therapy - The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response. | 2017-02-09 |
20170035877 | SOLUBLE HIV-1 ENVELOPE GLYCOPROTEIN TRIMERS - The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 2017-02-09 |
20170035878 | Multi-Functional Mucosal Vaccine Platform - An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyRI-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains. | 2017-02-09 |
20170035879 | Formulations that Provide Support During Vaccinations and Adaptive Immune System Response - The present invention provides formulations that support an individuals body during routine vaccination and adaptive immune response. The individuals who can benefit front these formulations are infants, children and adults. The formulations comprise ingredients that can be administered prior to, concurrent with or subsequent to the vaccination. The formulations of the present invention preferably act by targeting enzymatic reactions an individual's various metabolic pathways, maintaining balance between oxidative stress and methylation, maintaining balance between Th1 and Th2 responses, or a combination thereof during vaccination and adaptive immune response. | 2017-02-09 |
20170035880 | LIPOTEICHOIC ACID FROM LACTOBACILLI AS A POTENT IMMUNE STIMULATORY ADJUVANT FOR VACCINE DEVELOPMENT - The present invention provides compositions and methods useful for vaccination and generating CD8+ T lymphocyte immune memory against one or more antigens utilizing lipoteichoic acid. | 2017-02-09 |
20170035881 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor - Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer. | 2017-02-09 |
20170035882 | METHOD FOR THE TREATMENT OR PREVENTION OF INFECTION-RELATED IMMUNE CONDITIONS USING A COMPOSITION COMPRISING IGM - Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM. | 2017-02-09 |
20170035883 | Methods and Compositions for Treating Conditions of the Eye - Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody. | 2017-02-09 |
20170035884 | AQUEOUS GELLING COMPOSITIONS OF SOLUBLE ACTIVE PHARMACEUTICAL PEPTIDES PROVIDING MODIFIED RELEASE - An aqueous pharmaceutical composition comprising a peptide and one or more water-soluble or water-dispersible gelling agents. | 2017-02-09 |
20170035885 | HIGHLY CONCENTRATED STABLE MELOXICAM SOLUTIONS - Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness. | 2017-02-09 |
20170035886 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF - The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer. | 2017-02-09 |
20170035887 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES - The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. | 2017-02-09 |